All News
Deucravacitinib (TYK2i) - phase II trial for PsA ⭐️ACR20, 50, 70 response ⭐️HAQ-DI response ⭐️LEI/SPARCC response ⭐️MDA response Abs#OP0227 #EULAR2021 @RheumNow
Robert B Chao, MD doctorRBC ( View Tweet)
Risankizumab (IL-23i) phase III trial for PsA inadequate response to biologic
⭐️ACR20, 50,70 response
⭐️significant resolution of enthesitis/dactylitis
Abs#OP0228
#EULAR2021 @RheumNow
Robert B Chao, MD doctorRBC ( View Tweet)
Latest GRAPPA guidelines for treatment of PsA
Abs#OP0229
#EULAR2021 @RheumNow https://t.co/YlHHQsFGC8
Robert B Chao, MD doctorRBC ( View Tweet)
What can define +MRI for active spine lesions in axSpA?
*⃣ BME in >/=4 vertebral corners (VCs)
*⃣BME in >/= 3 VCs if w/ at least 1 non-corner inflamm lesion
*⃣BME in >/=1 VC if w/ at least 2 VC fat lesions
Such cut-offs achieve >/= 95% specificity
OP0252. #EULAR2021 @Rheumnow https://t.co/5CTan2BgLK
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Lower ILD incidence in PsA than RA in a large Nordic registry
⭐️ No significant ⬆️ in ILD in those using MTX
Abs#OP0222
#EULAR2021 @RheumNow https://t.co/lgGhu1Hmd6
Robert B Chao, MD doctorRBC ( View Tweet)
Key points on phenotypes in PsA per Dr. Dafna Gladman:
⭐️Oligoarticular & polyarticular PsA pts have the same burden of dz
⭐️Dactylitis assoc w/ greater dz severity & US synovitis + erosive changes in DMARD-naive early PsA pts
#EULAR2021 @RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Dr Dehlin presents Swedish data showing ⬆️ risk of all cause mortality (HR: 1.08 (95% CL: 1.05-1.11) and most comorbidities but a ⬇️ risk dementia in gout 0.68 (0.60-0.77) @RheumNow #EULAR2021 Abstr#OP0208 https://t.co/0ojpSbfIHM
Richard Conway RichardPAConway ( View Tweet)
#EULAR2021 Gender differences in chronic #arthritis 🙋🙋♂️
▶️ POS1061: The Italian prospective SIRENA study: women do worse at the onset of #psoriaticarthritis 🇮🇹
▶️ POS0208: The Austrian Registry BIOREG: women showed lower response rates to #TNFi 🇦🇹
> LA https://t.co/JNxrqimp2Y
ARD & RMD Open ARD_BMJ ( View Tweet)
Phenotypes in axPsA per Dr. Gladman:
⭐️15% develop axial dz at 10y: # of radiographic damaged joints, periostitis, & ⬆️ESR predictive. HLA-B27 no longer predictive
⭐️Buttock pain & IBD more common in axial dz
⭐️M had more axial dz + radiographic damage
#EULAR2021. @Rheumnow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Dr Deodhar on upadacitinib in axial PsA. Appears to be effective in combined analysis of SELECT-PsA 1 and 2. @RheumNow #EULAR2021 Abstr#0233 https://t.co/fBMWVb3oBd
Richard Conway RichardPAConway ( View Tweet)
Israeli study of all cause mortality in PsA vs general population
⭐️no increased mortality in PsA group
⭐️leading causes of death was cancer in both groups
⭐️age, male sex, BMI, socioeconomic status, PsO associated with ⬆️mortality, NOT DMARDs
Abs#OP0219
#EULAR2021 @RheumNow
Robert B Chao, MD doctorRBC ( View Tweet)
Metabolomic profiling for PsA showed vLDL, triglycerides; apolipoprotein B, glycoprotein acetylene associated with increased CV events…
Do you monitor cholesterol levels in your PsA pts?
Abs#OP0221
#EULAR2021 @RheumNow
Robert B Chao, MD doctorRBC ( View Tweet)
Talk about unmet need. We must get better Rx for #Sogren’s Syndrome! Large survey show quality of life v poor in SS & correlates with degree of dryness in lacrimal & salivary glands POS0102 #EULAR2021 @eular_org @RheumNow
Janet Pope Janetbirdope ( View Tweet)
If we want drugs to be effective in #Sjogren’s Syndrome we need to see activity. The #Eular SS disease activity index ~ESSDAI in 511 SS pts found >50% w moderate to severe values BUT how much is Reversible ie fibro, fatigue, scarred glands? POS0105 @RheumNow @eular_org #EULAR2021
Janet Pope Janetbirdope ( View Tweet)
Disappointed to have missed lots of interesting sessions at Day 3 #EULAR2021 but look forward to catching up, starting with the difficult-to-treat #rheumatoidarthritis session! I particularly like this helpful summary on complexities & factors to consider in patients with D2T RA. https://t.co/H8n9Q2QNDW
Mrinalini Dey DrMiniDey ( View Tweet)
Cool special effects in #EULAR2021 symposium: A practical guide to the use of JAKi in RA & SpA. Beamed in & out of talk like #StarTrek @eular_org @RheumNow https://t.co/y4qToeFKE7
Janet Pope Janetbirdope ( View Tweet)
What does this graph represent to you? To me: we have a whole lot of PsA that all work equally well..
It’s time for more personalized approach to PsA treatment!
Excellent talk by @DrLauraCoates
Abs#OP6937
#EULAR2021 @RheumNow https://t.co/1NKLfmH2y5
Robert B Chao, MD doctorRBC ( View Tweet)
Day 3 #EULAR2021 - A dose of #physicalactivity 🏃🏼 before conference to keep me sane with all interesting stuff presented https://t.co/jew2T9lnwB
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Similar efficacy of PsA enthesitis treatment between adalimumab and secukinumab
⭐️mean change and resolution of enthesitis similar
⭐️resolution of equal but ⬇️ in pts with ⬆️ baseline enthesitis activity
⭐️rate of relapse ⬇️ and similar
Abs#POS0194
#EULAR2021 @RheumNow https://t.co/uPE4kmotCY
Robert B Chao, MD doctorRBC ( View Tweet)
Interesting small study on US assessment of Achilles of PsA vs normal pts after exercise
⭐️significant different of PD signal in PsA group
⭐️5 non-PsA pts still had PD🤔
Would be interesting to further classify differences in PD intensity…
Abs#POS1058
#EULAR2021 @RheumNow https://t.co/SLhqq4wgCl
Robert B Chao, MD doctorRBC ( View Tweet)
